Welcome to our dedicated page for Lakewood-Amedex Biotherapeutics news (Ticker: LABT), a resource for investors and traders seeking the latest updates and insights on Lakewood-Amedex Biotherapeutics stock.
Lakewood-Amedex Biotherapeutics reports developments tied to its clinical-stage antimicrobial pipeline and public-company status. News items cover the Bisphosphocin® class, antimicrobial resistance data for the lead compound Nu-3, and the company’s development work for infected diabetic foot ulcers, with additional platform references to complicated urinary tract infection and pulmonary infections.
Company updates also include Nasdaq listing activity under the LABT symbol and governance changes following its direct listing. These announcements describe the company’s transition into a Nasdaq-traded biotechnology issuer while continuing to center on its proprietary antimicrobial platform.
Lakewood-Amedex Biotherapeutics (LABT) received central and site IRB approvals and confirmed clinical site readiness to begin a Phase 2a trial of Nu-3 for mildly infected diabetic foot ulcers. The study will evaluate the safety and efficacy of Nu-3, the company’s lead product candidate, in patients with iDFU, a condition described as a leading cause of lower-limb amputations worldwide. The trial is designed to build on positive preclinical safety data and early exploratory findings in which Nu-3 was well-tolerated and showed trends of improved antimicrobial response and wound healing. Nu-3 is a proprietary topical gel that uses a mechanism of action aimed at destabilizing microbial cell membranes, which is described as providing a high barrier to the development of antimicrobial resistance. The company states that this development remains aligned with federal mandates from the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria for innovative, resistance-evading therapies.
Lakewood-Amedex Biotherapeutics (LABT) will present at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026, in New York City.
CEO Kelvin Cooper, Ph.D., will deliver a virtual presentation on the company’s Bisphosphocin® antimicrobial platform. During the conference, he will also hold one-on-one meetings with registered investors and potential partners to discuss the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) highlighted new resistance data for its Phase 2-ready antimicrobial candidate Nu-3, being developed for infected diabetic foot ulcers (iDFU). Nu-3 targets and disrupts bacterial membranes via a unique, physical mechanism of action and has shown a high barrier to resistance.
According to Lakewood-Amedex Biotherapeutics, Nu-3 did not induce resistance in a serial passage experiment and demonstrated broad-spectrum in vitro activity against bacteria harboring diverse resistance mechanisms, including target modifications (e.g., vanA/vanB, mec, rpoB, PBP2x), β-lactamase variants (NDM, ESBL, AmpC, CRE), sul2-mediated metabolic resistance, and efflux pumps. The company positions its Bisphosphocin® platform as aligned with the U.S. National Action Plan on Combating Antibiotic-Resistant Bacteria discussed at the June 16, 2026 PACCARB meeting.
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) reported preclinical safety results for its Nu-3 gel, a Bisphosphocin®-based topical antimicrobial being developed for infected diabetic foot ulcers (iDFU). The FDA-required safety study showed Nu-3 was well tolerated at dose levels substantially higher than those planned for the upcoming Phase 2a trial and did not inhibit wound healing.
According to the company, systemic exposure to Nu-3 was very low, supporting a low potential for systemic side effects. Based on combined in vitro, in vivo and safety data, Lakewood-Amedex Biotherapeutics has selected 2%, 5% and 10% Nu-3 gel concentrations for evaluation in a Phase 2a iDFU study that is nearing initiation.
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) voiced support for the reintroduction of the bipartisan PASTEUR Act, which aims to incentivize development of new antimicrobials against antimicrobial resistance (AMR).
The company highlighted its proprietary Bisphosphocin® platform and lead candidate Nu-3, now preparing for Phase 2 as a topical therapy for infected diabetic foot ulcers.
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT), a clinical-stage biotech developing Bisphosphocin® antimicrobials, appointed David G. Armstrong, DPM, M.D., Ph.D. as Study Chair for its Phase 2a trial of Nu-3 in infected diabetic foot ulcers.
Armstrong will also serve as Scientific Advisor for the iDFU program. The proof-of-concept Phase 2a trial will test topical Nu-3 gel at 2%, 5% and 10% to assess safety and efficacy and support a potential Phase 2b study.
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) received a new Australian composition of matter patent for its Bisphosphocin® antimicrobial compounds, covering uses in infections including complicated urinary tract and pulmonary infections.
The patent, issued March 5, 2026, expands a portfolio of 72 granted and 29 pending patents worldwide, supporting development against antimicrobial resistance.
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT), a clinical-stage biotech focused on Bisphosphocin® antimicrobials, will present at the Life Sciences Virtual Investor Forum on June 25, 2026, at 11:30 AM EDT.
CEO Kelvin Cooper will discuss the company’s growth strategy and lead candidate Nu-3, a topical gel advancing into Phase 2 trials for infected diabetic foot ulcers.
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) expanded its global IP portfolio for lead candidate Nu-3, a Bisphosphocin antimicrobial gel for mildly infected diabetic foot ulcers. Two new patents in Australia and New Zealand bring the Nu-3 gel formulation total to 27 granted patents across major regions.
The company now holds 71 granted patents and 28 pending, supporting advancement of Nu-3 into a Phase 2 clinical trial and reinforcing protection of its Bisphosphocin platform worldwide.
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) reported positive data supporting advancement of its lead antimicrobial candidate Nu-3 for mildly infected diabetic foot ulcers. The company completed key formulation, delivery and cGMP manufacturing steps, improved cost of goods, and generated multikilogram gel supplies suitable for a planned Phase 2 clinical trial.
Nu-3 drug substance shows at least five-year stability, while the gel formulation is stable for at least two years with undetectable bioburden and no added preservatives.